• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

针对 BCL-2 和 EGFR 的双特异性反义寡核苷酸处理后 LNCaP 细胞中分化的前列腺抗原表达。

Differentiated prostatic antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against BCL-2 and EGFR.

机构信息

Division of Cellular Biology, Hektoen Institute for Medical Research, 2240 West Ogden Avenue, 2'nd Floor, Chicago, IL 60612, USA.

出版信息

Med Oncol. 2012 Jun;29(2):835-41. doi: 10.1007/s12032-011-9977-x. Epub 2011 May 15.

DOI:10.1007/s12032-011-9977-x
PMID:21573974
Abstract

Antisense oligonucleotides (oligos) have been administered against in vivo and in vitro prostate cancer models employing LNCaP and PC-3 cell lines. While most oligos consist of a single mRNA binding site targeting a single gene product or those with sequence homology, our lab has developed bispecific oligos directed toward two unrelated proteins. In LNCaP cells, we initially identified bispecifics that increased the expression of prostate-specific membrane antigen (PSMA) while not affecting secreted prostate-specific antigen (PSA). We postulated that surface antigen expression is increased by bispecifics able to form double-stranded regions, acting as interferon (IFN-γ) inducers. In other systems, when induced, IFN-γ promotes cell surface antigen expression, including HLA and receptors for tumor necrosis factor. To test this hypothesis, we measured the effect of oligo treatment on both IFN-γ induction and the expression of another secreted product of differentiated prostate cells, prostatic acid phosphatase (PAP). This study initially evaluated the inhibition of in vitro propagating LNCaP cells employing mono- and bispecific oligos directed against bcl-2 (the second bispecific binding site was against the epidermal growth factor receptor). Employing RT-PCR, the expression of non-targeted proteins encoded by mRNA for PSMA, PSA, PAP, and IFN-γ was subsequently valuated. When LNCaP prostate tumor cells were incubated with oligos and compared to lipofectin-containing controls significant growth inhibition resulted. Employing RT-PCR, the levels of mRNA encoding PSMA were unexpectedly found to be elevated following treatment with the bispecific oligos but not with a monospecific directed solely against bcl-2. No differences were detected in mRNA levels encoding PSA following treatment with either oligo type. IFN-γ was significantly induced only by bispecific oligos, and PAP expression was similar to PSA. These data support the hypothesis that double strand-forming bispecific oligos induce IFN-γ that enhances cell surface PSMA expression. Expression of tumor-associated surface antigens could increase their recognition and targeting by immunologic defense mechanisms and increase the effectiveness of tumor vaccines.

摘要

反义寡核苷酸(oligos)已被用于体内和体外前列腺癌模型,使用 LNCaP 和 PC-3 细胞系。虽然大多数 oligos 由针对单个基因产物或具有序列同源性的单个 mRNA 结合位点组成,但我们实验室已经开发了针对两个不相关蛋白质的双特异性 oligos。在 LNCaP 细胞中,我们最初确定了增加前列腺特异性膜抗原(PSMA)表达而不影响分泌的前列腺特异性抗原(PSA)的双特异性 oligos。我们假设,能够形成双链区域的双特异性 oligos 会增加表面抗原表达,其作用类似于干扰素(IFN-γ)诱导剂。在其他系统中,当被诱导时,IFN-γ促进细胞表面抗原表达,包括 HLA 和肿瘤坏死因子受体。为了验证这一假设,我们测量了 oligo 处理对 IFN-γ诱导和分化前列腺细胞的另一种分泌产物前列腺酸性磷酸酶(PAP)表达的影响。这项研究最初评估了针对 bcl-2 的单和双特异性 oligos 对体外增殖的 LNCaP 细胞的抑制作用(第二个双特异性结合位点针对表皮生长因子受体)。采用 RT-PCR,随后评估了 PSMA、PSA、PAP 和 IFN-γ 的 mRNA 编码的非靶向蛋白的表达。当 LNCaP 前列腺肿瘤细胞与 oligos 孵育并与含有脂质体的对照相比时,导致显著的生长抑制。采用 RT-PCR,出乎意料地发现,在用双特异性 oligos 处理后,PSMA 的 mRNA 编码水平升高,但在用仅针对 bcl-2 的单特异性 oligos 处理后没有升高。在用任何一种 oligo 类型处理后,PSA 的 mRNA 水平均未检测到差异。IFN-γ 仅由双特异性 oligos 显著诱导,PAP 表达与 PSA 相似。这些数据支持这样的假设,即形成双链的双特异性 oligos 诱导 IFN-γ,增强细胞表面 PSMA 表达。肿瘤相关表面抗原的表达可以增加其被免疫防御机制识别和靶向的能力,并提高肿瘤疫苗的有效性。

相似文献

1
Differentiated prostatic antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against BCL-2 and EGFR.针对 BCL-2 和 EGFR 的双特异性反义寡核苷酸处理后 LNCaP 细胞中分化的前列腺抗原表达。
Med Oncol. 2012 Jun;29(2):835-41. doi: 10.1007/s12032-011-9977-x. Epub 2011 May 15.
2
Increased prostate-specific membrane antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against bcl-2 and EGFR.经针对 bcl-2 和 EGFR 的双特异性反义寡核苷酸处理后,LNCaP 细胞中前列腺特异性膜抗原表达增加。
Med Oncol. 2010 Dec;27(4):1212-8. doi: 10.1007/s12032-009-9361-2. Epub 2009 Nov 24.
3
Bispecific oligonucleotides may induce interferon expression in LNCaP cells enhancing surface antigen expression: effect of intrastrand base pair complementarity.双特异性寡核苷酸可能会在 LNCaP 细胞中诱导干扰素表达,增强表面抗原表达:链内碱基互补配对的影响。
In Vivo. 2011 Jan-Feb;25(1):61-7.
4
Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors.具有针对自分泌调节生长途径和bcl-2的结合位点的双特异性反义寡核苷酸用于治疗前列腺肿瘤。
Med Oncol. 2007;24(2):189-96. doi: 10.1007/BF02698039.
5
Bispecific antisense oligonucleotides have activity comparable to monospecifics in inhibiting expression of BCL-2 in LNCaP cells.双特异性反义寡核苷酸在抑制 LNCaP 细胞中 BCL-2 的表达方面具有与单特异性药物相当的活性。
In Vivo. 2010 Jul-Aug;24(4):489-93.
6
Bax expression remains unchanged following antisense treatment directed against BCL-2.针对 BCL-2 的反义治疗后 Bax 的表达保持不变。
Med Oncol. 2011 Sep;28(3):852-8. doi: 10.1007/s12032-010-9543-y. Epub 2010 Apr 27.
7
Treatment of MCF-7 breast cancer cells employing mono- and bispecific antisense oligonucleotides having binding specificity toward proteins associated with autocrine regulated growth and BCL-2.使用对与自分泌调节生长和BCL-2相关的蛋白质具有结合特异性的单特异性和双特异性反义寡核苷酸治疗MCF-7乳腺癌细胞。
Med Oncol. 2008;25(2):182-6. doi: 10.1007/s12032-007-9018-y. Epub 2007 Oct 30.
8
Multigene targeting of signal transduction pathways for the treatment of breast and prostate tumors: comparison between combination therapies employing bispecific oligonucleotides with either Rapamycin or Paclitaxel.用于治疗乳腺和前列腺肿瘤的信号转导通路多基因靶向:使用双特异性寡核苷酸与雷帕霉素或紫杉醇联合治疗的比较
Med Oncol. 2009;26(2):124-30. doi: 10.1007/s12032-008-9088-5. Epub 2008 Aug 7.
9
Effects of BCL-2 suppression by antisense oligonucleotides on additional regulators of apoptosis compensatory change in non-targeted protein expression.反义寡核苷酸抑制 BCL-2 对凋亡其他调节因子的作用:非靶向蛋白表达的代偿性变化。
In Vivo. 2011 Sep-Oct;25(5):725-32.
10
Combination chemotherapy employing bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors.采用具有针对自分泌调节生长途径和bcl-2的结合位点的双特异性反义寡核苷酸进行联合化疗以治疗前列腺肿瘤。
Med Oncol. 2007;24(4):372-8. doi: 10.1007/s12032-007-0023-y.

引用本文的文献

1
Advances and applications of RNA vaccines in tumor treatment.RNA 疫苗在肿瘤治疗中的进展和应用。
Mol Cancer. 2024 Oct 9;23(1):226. doi: 10.1186/s12943-024-02141-5.
2
Progress in the Use of Antisense Oligonucleotides for Vaccine Improvement.反义寡核苷酸在疫苗改良中的应用进展。
Biomolecules. 2020 Feb 17;10(2):316. doi: 10.3390/biom10020316.
3
Emerging roles of human prostatic Acid phosphatase.人前列腺酸性磷酸酶的新作用

本文引用的文献

1
Does the prostate retain an endogenous antiviral defense system suggesting a past viral etiology for cancer?前列腺是否保留了一种内源性抗病毒防御系统,提示癌症有过去的病毒病因?
Med Hypotheses. 2011 Mar;76(3):368-70. doi: 10.1016/j.mehy.2010.10.042. Epub 2010 Nov 19.
2
Bispecific antisense oligonucleotides have activity comparable to monospecifics in inhibiting expression of BCL-2 in LNCaP cells.双特异性反义寡核苷酸在抑制 LNCaP 细胞中 BCL-2 的表达方面具有与单特异性药物相当的活性。
In Vivo. 2010 Jul-Aug;24(4):489-93.
3
Multigene targeting of signal transduction pathways for the treatment of breast and prostate tumors: comparison between combination therapies employing bispecific oligonucleotides with either Rapamycin or Paclitaxel.
Biomol Ther (Seoul). 2013 Jan;21(1):10-20. doi: 10.4062/biomolther.2012.095.
4
Translational Approaches towards Cancer Gene Therapy: Hurdles and Hopes.癌症基因治疗的转化方法:障碍与希望。
Bioimpacts. 2012;2(3):127-43. doi: 10.5681/bi.2012.025. Epub 2012 Sep 22.
5
In LNCaP cells enhanced expression of both androgen receptor and costimulatory protein p300 compensate for antisense oligonucleotide suppression of bcl-2.在 LNCaP 细胞中,雄激素受体和共刺激蛋白 p300 的表达增强弥补了反义寡核苷酸对 bcl-2 的抑制作用。
Ther Adv Urol. 2011 Dec;3(6):243-50. doi: 10.1177/1756287211426155.
6
Compensatory and non-compensatory effects on protein expression following BCL-2 suppression by antisense oligonucleotides.反义寡核苷酸抑制 BCL-2 后对蛋白质表达的补偿和非补偿效应。
Med Oncol. 2012 Sep;29(3):2284-90. doi: 10.1007/s12032-011-0097-4. Epub 2011 Oct 30.
用于治疗乳腺和前列腺肿瘤的信号转导通路多基因靶向:使用双特异性寡核苷酸与雷帕霉素或紫杉醇联合治疗的比较
Med Oncol. 2009;26(2):124-30. doi: 10.1007/s12032-008-9088-5. Epub 2008 Aug 7.
4
Treatment of MCF-7 breast cancer cells employing mono- and bispecific antisense oligonucleotides having binding specificity toward proteins associated with autocrine regulated growth and BCL-2.使用对与自分泌调节生长和BCL-2相关的蛋白质具有结合特异性的单特异性和双特异性反义寡核苷酸治疗MCF-7乳腺癌细胞。
Med Oncol. 2008;25(2):182-6. doi: 10.1007/s12032-007-9018-y. Epub 2007 Oct 30.
5
Combination chemotherapy employing bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors.采用具有针对自分泌调节生长途径和bcl-2的结合位点的双特异性反义寡核苷酸进行联合化疗以治疗前列腺肿瘤。
Med Oncol. 2007;24(4):372-8. doi: 10.1007/s12032-007-0023-y.
6
Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors.具有针对自分泌调节生长途径和bcl-2的结合位点的双特异性反义寡核苷酸用于治疗前列腺肿瘤。
Med Oncol. 2007;24(2):189-96. doi: 10.1007/BF02698039.
7
Targeting of biotinylated oligonucleotides to prostate tumors with antibody-based delivery vehicles.使用基于抗体的递送载体将生物素化寡核苷酸靶向递送至前列腺肿瘤。
J Drug Target. 2007 Jun;15(5):342-50. doi: 10.1080/10611860701350099.
8
Bispecific antisense oligonucleotides with multiple binding sites for the treatment of prostate tumors and their applicability to combination therapy.具有多个结合位点的双特异性反义寡核苷酸用于治疗前列腺肿瘤及其在联合治疗中的适用性。
Methods Find Exp Clin Pharmacol. 2006 Oct;28(8):515-8. doi: 10.1358/mf.2006.28.8.1003571.
9
Synthesis of branched antisense oligonucleotides having multiple specificities. Treatment of hormone insensitive prostate cancer.具有多种特异性的支链反义寡核苷酸的合成。激素不敏感型前列腺癌的治疗。
Med Hypotheses. 2006;67(6):1375-80. doi: 10.1016/j.mehy.2006.05.055. Epub 2006 Jul 25.
10
Construction of a bispecific antisense oligonucleotide containing multiple binding sites for the treatment of hormone insensitive prostate tumors.构建一种含有多个结合位点的双特异性反义寡核苷酸用于治疗激素不敏感型前列腺肿瘤。
Med Hypotheses. 2005;65(5):905-7. doi: 10.1016/j.mehy.2004.12.032.